Reversal of Multidrug Resistance by an Immunosuppressive Agent FK-506

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1992 Jan 1

PMID 1370765

Citations 14

Authors

M Naito

A Yamazaki

T Danki

T Tsuruo

Affiliations

Soon will be listed here.

Abstract

FK-506, a novel immunosuppressive agent, was examined for its reversing effect on multidrug-resistant tumor cells. FK-506 at 3 microM completely reversed the resistance against vincristine (VCR) in vitro in VCR-resistant mouse leukemia P388 cells (P388/VCR). FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro. FK-506 was also effective in modulating sensitivity to ADM in AD10 cells in vitro. FK-506 enhanced the chemotherapeutic effect of VCR in P388/VCR-bearing mice. When 20 mg/kg FK-506 was combined with 200 micrograms/kg VCR, a T/C value of 151% was obtained. Under the protocol used in this study, FK-506 was more potent than cyclosporin A (CsA) and verapamil. FK-506 inhibited [3H]azidopine binding to P-glycoprotein efficiently. The binding of VCR to K562/ADM plasma membrane was inhibited by FK-506 as effectively as by CsA. Moreover, the accumulation of VCR in AD10 cells was increased by FK-506 as efficiently as that of CsA and verapamil. These results indicate that FK-506 directly interacts with P-glycoprotein like CsA and verapamil, inhibits the active efflux of vincristine from resistant cells, increases the vincristine accumulation in resistant cells, and thus overcomes multidrug resistance in vitro and in vivo.

Citing Articles

FK506 Attenuates the MRP1-Mediated Chemoresistant Phenotype in Glioblastoma Stem-Like Cells.

Torres A, Arriagada V, Erices J, Toro M, Rocha J, Niechi I Int J Mol Sci. 2018; 19(9).

PMID: 30208561 PMC: 6164673. DOI: 10.3390/ijms19092697.

Inhibitory effects of neochamaejasmin B on P-glycoprotein in MDCK-hMDR1 cells and molecular docking of NCB binding in P-glycoprotein.

Pan L, Hu H, Wang X, Yu L, Jiang H, Chen J Molecules. 2015; 20(2):2931-48.

PMID: 25679052 PMC: 6272504. DOI: 10.3390/molecules20022931.

Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells.

Ohtani H, Ikegawa T, Honda Y, Kohyama N, Morimoto S, Shoyama Y Pharm Res. 2007; 24(10):1936-43.

PMID: 17492365 DOI: 10.1007/s11095-007-9320-6.

Farnesyltransferase inhibitors reverse taxane resistance.

Marcus A, OBrate A, Buey R, Zhou J, Thomas S, Khuri F Cancer Res. 2006; 66(17):8838-46.

PMID: 16951201 PMC: 1861825. DOI: 10.1158/0008-5472.CAN-06-0699.

Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D.

Kurosawa K, Takahashi K, Tsuda E, Tomida A, Tsuruo T Jpn J Cancer Res. 2001; 92(11):1235-41.

PMID: 11714449 PMC: 5926656. DOI: 10.1111/j.1349-7006.2001.tb02145.x.

References

Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, OKUHARA M . FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987; 40(9):1249-55. DOI: 10.7164/antibiotics.40.1249. View

Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T . FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987; 40(9):1256-65. DOI: 10.7164/antibiotics.40.1256. View

Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y . Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 1983; 43(6):2905-10. View

Bunjes D, Hardt C, Rollinghoff M, Wagner H . Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol. 1981; 11(8):657-61. DOI: 10.1002/eji.1830110812. View

Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y . Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982; 42(11):4730-3. View

Naito M, Hamada H, Tsuruo T . ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J Biol Chem. 1988; 263(24):11887-91. View

Twentyman P . Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins. Br J Cancer. 1988; 57(3):254-8. PMC: 2246508. DOI: 10.1038/bjc.1988.55. View

Tsuruo T, Saito H . Characteristics of vincristine resistance in vincristine resistant human myelogenous leukemia K562. Anticancer Res. 1986; 6(4):637-41. View

Pastan I, Gottesman M . Multiple-drug resistance in human cancer. N Engl J Med. 1987; 316(22):1388-93. DOI: 10.1056/NEJM198705283162207. View

10.

Slater L, Sweet P, Stupecky M, Gupta S . Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest. 1986; 77(4):1405-8. PMC: 424510. DOI: 10.1172/JCI112450. View

11.

Standaert R, Galat A, Verdine G, Schreiber S . Molecular cloning and overexpression of the human FK506-binding protein FKBP. Nature. 1990; 346(6285):671-4. DOI: 10.1038/346671a0. View

12.

Yusa K, Tsuruo T . Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 1989; 49(18):5002-6. View

13.

Tropschug M, Wachter E, Mayer S, Schonbrunner E, Schmid F . Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. Nature. 1990; 346(6285):674-7. DOI: 10.1038/346674a0. View

14.

Tsuruo T, Kawabata H, Hamada H, UTAKOJI T . Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res. 1986; 77(7):682-92. View

15.

Sonneveld P, Nooter K . Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br J Haematol. 1990; 75(2):208-11. DOI: 10.1111/j.1365-2141.1990.tb02650.x. View

16.

Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y . Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981; 41(5):1967-72. View

17.

Endicott J, Ling V . The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989; 58:137-71. DOI: 10.1146/annurev.bi.58.070189.001033. View

18.

Reem G, Cook L, Vilcek J . Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A. Science. 1983; 221(4605):63-5. DOI: 10.1126/science.6407112. View

19.

Britton S, Palacios R . Cyclosporin A--usefulness, risks and mechanism of action. Immunol Rev. 1982; 65:5-22. DOI: 10.1111/j.1600-065x.1982.tb00425.x. View

20.

Tsuruo T . Circumvention of drug resistance with calcium channel blockers and monoclonal antibodies. Cancer Treat Res. 1989; 48:73-95. DOI: 10.1007/978-1-4613-1601-5_6. View